- Home
- HYMC vs OGN Comparison
HYMC vs OGN Comparison
Compare HYMC & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYMC | OGN |
|---|---|---|
| Founded | N/A | 1923 |
| Country | United States | United States |
| Employees | 51 | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.5B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HYMC | OGN |
|---|---|---|
| Price | $20.53 | $13.57 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $11.40 |
| AVG Volume (30 Days) | 1.5M | ★ 2.6M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.95 |
| Revenue | N/A | ★ $6,216,000,000.00 |
| Revenue This Year | N/A | $0.45 |
| Revenue Next Year | N/A | $1.67 |
| P/E Ratio | ★ N/A | $14.27 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.34 | $5.69 |
| 52 Week High | $58.73 | $13.60 |
Technical Indicators
Market Signals| Indicator | HYMC | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 43.27 | 62.42 |
| Support Level | $18.02 | $13.46 |
| Resistance Level | $22.37 | $13.60 |
| Average True Range (ATR) | 1.38 | 0.03 |
| MACD | 0.29 | -0.01 |
| Stochastic Oscillator | 47.84 | 72.22 |
Price Performance
Historical ComparisonAbout HYMC Hycroft Mining Holding Corporation
Hycroft Mining Holding Corp is a United States-based gold and silver exploration-stage issuer. The company owns and is focused on developing its property, the Hycroft Mine, located northwest of Winnemucca, Nevada.
About OGN Organon & Co.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.